Q-omics provides the consensus-scored SUMO1P3 profile across patient tissues and cancer cell-line models. SUMO1P3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SUMO1P3 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, SUMO1P3 RNA expression shows 18,132 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where SUMO1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUMO1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUMO1P3 survival associations across molecular data types. SUMO1P3 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUMO1P3 RNA expression–survival associations across cancer types. High SUMO1P3 expression shows unfavorable associations in ACC, KIRP, HNSC, UVM and LUSC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SUMO1P3 RNA expression.
This table summarizes SUMO1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SUMO1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUMO1P3 shows lower tumor expression in KICH and higher tumor expression in BRCA, LUAD, CHOL, BLCA and STAD. The KICH box plot shows higher SUMO1P3 RNA expression in normal versus tumor tissue (log2 FC = −1.122, t-test p < 0.001).
This table shows molecular features associated with SUMO1P3 in patient tissues and cancer cell lines. In patient samples, SUMO1P3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SUMO1P3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in OVARY.
